Misha V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, Russia. Dr. Mikhail V. Blagosklonny has then
Immigrated to the United States, where he received the prestigious Fogarty Fellowship from the National Institutes of Health.
During his fellowship in Leonard Neckers’ laboratory at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Various biomedical themes, suchas targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last author for a clinical phase I/II
After authoring seven papers during a brief yet resulting
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to cooperate with Tito Fojo. Together, they
Published 26 papers. Moreover, Dr. Misha Blagosklonny published anumber of experimental research papers and theoretical papers as sole
Writer. Those sole-author papers
Included two important topics.
The first of those focused on selectively killing cancer
Cells with deregulated cell cycle or drug resistance by
Exploiting their resistance. The outcomes and underlying
Concept were so revolutionary that they were improperly cited by
Other scientists as “reversal of resistance, ” even though the publication was
Named, “Exploiting of drug resistance instead of its reversal. ” One big
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint publication in 2001.
The second topic throughout Dr. Blagosklonny’s sole-author publications
Is a research method to create knowledge by
Bringing several facts together from seemingly unrelated fields.
This results in new notions with testable forecasts, which in
Turn can be “tested” via analyzing the literature further. Likewise, the
Notion was co-authored by Arthur Pardee in a 2002 publication in Nature. The
First success of the new research method was the description of the feedback
Regulation of p53, as supported by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Important outcome discovered by Dr.
Blagosklonny’s research methods is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exclusively well-tolerated
Anti-aging medicine, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny recognition for
“connecting dots that others do not even see. ”
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He agreed to accept responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, prior to receiving another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
Since joining Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) via
Preventing organism aging — in other words, “preventing cancer
By remainng young. ” His lab closely collaborated with
Andrei Gudkov’s and performed research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This led to the discovery of extra anti-aging
Medications beyond rapamycin. The cell culture studies were
Accompanied by studies in mice, including several models like
Normal and aging mice, p53-deficient mice, and mice on a high-fat diet.
Dr. Mikhail Blagosklonny has also published extensively on the stoppage of cellular
Senescence by rapamycin and other mTOR inhibitors, life
Extension and cancer cure in mice, and combinations of anti-
Aging drugs to be used in humans. A
Rapamycin-based combination of seven clinically available drugs has
Been named the “Koschei Formula” and is now used for the treatment of aging in patients At the Alan Green Clinic in Little Neck, New York.